AnaptysBio (NASDAQ:ANAB) Stock, Quote.Headers.trade-ideas

AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

tech stocks

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ANAB

YUMC

Insiders Buying Yum China And 2 Other Stocks

UBS sign

Intraday Update

Movers

CLOV

FLUT

INTA

LPLA

MRCY

NKTX

PFGC

PRLD

QFIN

SDHC

SERV

VSCO

UBS Posts Upbeat Earnings, Joins Victoria&#39;s Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday

bulls ai2

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Small Cap

Economics

Federal Reserve

Tech

ETFs

ASML

US inflation eases in July, keeping Fed rate cut hopes alive. Stocks rise, yields stable, dollar gains against yen. Tech and small caps outperform.

S&amp;P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday

AnaptysBio Inc

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out<a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#8217;s insider transaction</a>s platform.
<h3 class="wp-block-heading">AnaptysBio</h3>
<ul>
<li>The Trade: AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) 10% owner Ecor1 Capital, LLC <a href="https://www.benzinga.com/quote/ANAB/analyst-ratings">acquired a total of 273,972 shares </a> at an average price of $36.50. To acquire these shares, it cost around $10 million.</li>
<li>What's Happening: On Aug. 14, the company announced a public offering of 2,750,498 shares of common stock at $36.50 per share.</li>
<li>What AnaptysBio Does: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology.</li>
</ul>
<h3 class="wp-block-heading">Forum Energy Technologies</h3>
<ul>
<li>The Trade: Forum Energy Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FET#NYSE">FET</a>) President and CEO Neal Lux acquired a total of 13,500 shares at an average price of $15.82. To acquire these shares, it cost around $213,570.</li>
<li>What's Happening: On Aug. 1, Forum Energy Technologies posted downbeat quarterly results.</li>
<li>What Forum Energy Technologies Does: Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries.</li>
</ul>
<h3 class="wp-block-heading">Yum China</h3>
<ul>
<li>The Trade: Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) General Manager, KFC Warton Wang <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 3,700 shares</a> at an average price of $34.67. To acquire these shares, it cost around $128,267.</li>
<li>What's Happening: On Aug 5, Yum China reported a second-quarter earnings beat and announced a CFO transition.</li>
<li>What Yum China Does: With almost 13,000 units and USD 10 billion in systemwide sales in 2022, Yum China is the largest restaurant chain in China.</li>
</ul>
Read More<a href="https://www.benzinga.com/markets/24/08/40420521/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">: </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40420521/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">Jim Cramer Recommends Buying Clorox: &#8216;CEO Has Done Remarkable Job&#8217;</a></li>
</ul>

Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Hold and raises the price target from $20 to $30.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on AnaptysBio, Raises Price Target to $30

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and maintains $55 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $55 Price Target

U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Wednesday.
Shares of UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) rose during Wednesday's session following strong s<a href="https://www.benzinga.com/news/earnings/24/08/40360422/ubs-q2-earnings-beats-wealth-management-shines-cost-savings-accelerate-more">econd-quarter earnings.</a>
UBS Group reported second-quarter FY24 sales of $11.9 billion, up 25% Y/Y, beating the consensus of $11.3 billion.
Underlying operating profit before tax reached $2.06 billion, significantly higher than $891 million a year ago. EPS of 34 cents beat the consensus of 12 cents.
UBS shares gained 5.6% to $30.89 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) shares jumped 29% to $13.40 after the company announced a partnership with Shake Shack to deliver products using autonomous delivery robots through Uber Eats.</li>
<li>Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) surged 21.9% to $41.43 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) gained 18.8% to $39.62 after the company announced a public offering of 2,750,498 shares of common stock at $36.50 per share.</li>
<li>Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) gained 17.1% to $22.33 after the company announced a new CEO and reported strong preliminary second-quarter financial results.</li>
<li>Nkarta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) surged 13.7% to $5.65 following upbeat quarterly earnings.</li>
<li>Marex Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) gained 13% to $23.56 after the company reported better-than-expected second-quarter financial results.</li>
<li>Smith Douglas Homes Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NASDAQ">SDHC</a>) jumped 12.2% to $36.54 after the company reported better-than-expected second-quarter revenue results..</li>
<li>Intapp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTA#NASDAQ">INTA</a>) gained 12.1% to $38.11 after the company reported strong fourth-quarter earnings and issued guidance.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) gained 11.3% to $2.2250 following quarterly results.</li>
<li>Performance Food Group Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) climbed 9.7% to $73.58 after the company reported better-than-expected fourth-quarter adjusted EPS results.</li>
<li>XP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) gained 8.7% to $20.05 following second-quarter results.</li>
<li>Prelude Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) gained 8.6% to $6.73.</li>
<li>Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) gained 8% to $206.76 after the company reported a year-over-year increase in second-quarter financial results..</li>
<li>Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) gained 7.9% to $80.39 following a report suggesting Mars is expected to pay $83.50 per share for the company.</li>
<li>Qifu Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) climbed 7.5% to $22.69 following second-quarter results.</li>
<li>LPL Financial Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) gained 7.1% to $213.53.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/news/24/08/40362640/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-stocks-with-over-3-dividend-yields"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40362640/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech Stocks With Over 3% Divi</a><a href="https://www.benzinga.com/news/24/08/40362640/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-stocks-with-over-3-dividend-yields">dend Yields</a></li>
</ul>

UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday

The July Consumer Price Inflation report made another step toward the Federal Reserve&#8217;s 2% target, though less pronounced than June&#8217;s, sustaining optimism for <a href="https://www.benzinga.com/topic/inflation">imminent interest rate cuts.</a>
Last month, a basket of goods and services purchased by U.S. consumers rose by 2.9% year-over-year, slightly below the previous and expected 3%, marking the fourth consecutive decline in annual inflation and the <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40365730/july-inflation-rate-falls-more-than-expected-supports-hopes-for-large-fed-rate-cu">lowest rate since March 2021.</a>
The annual core inflation rate also eased as anticipated, from 3.3% to 3.2%, the lowest since April 2021. 
However, the July report was marred by an increase in the shelter component, which, due to its significant weight in the basket, accounted for about 90% of the headline inflation rise.
The decline in annual inflation rates wasn&#8217;t sufficient to bolster expectations for a 50-basis-point rate cut in September. 
Market-implied probabilities for such a substantial cut dropped from 50% to 43% following the report, while the likelihood of a smaller 25-basis-point cut increased to 57%.
<h3 class="wp-block-heading">Market Reactions: Stocks Rise, Yields Steady, But Dollar Strengthens Against Yen</h3>
The July inflation data sparked a positive reaction in stocks, especially in the tech sector, with small caps outperforming their larger-cap counterparts. Treasury yields remained largely stable, while the U.S. dollar gained ground against the low-yielding Japanese yen.
Here are the premarket price reactions of the following exchange-traded funds (ETFs) to the inflation data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.2% at 09:10 a.m. in New York. Major premarket gainers were Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) and Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 7.2% and 5.5% respectively. </li>
<li>The tech-heavy Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.3%. Top gainers were Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) and Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) up 3.1% and 3%, respectively. </li>
<li>Semiconductors were the strongest-performing industry, with the VanEck Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>) up 0.9%. Micron Technology Inc. and ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) led gains, with the latter up 2.1%. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 0.5%, with Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) and AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) making the larger gains in the premarket, up 16% and 13%, respectively. </li>
<li>The Invesco CurrencyShares Japanese Yen Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXY#NYSE">FXY</a>) fell 0.2%.</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/08/40355203/stocks-now-dismiss-recession-fears-but-bond-markets-tell-investors-to-stay-on-alert">Stocks Now Dismiss Recession Fears, But Bond Markets Tell Investors To Stay On Alert</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday

WIIM

AnaptysBio shares are trading higher. The company announced a public offering of 2,750,498 shares of common stock at $36.50 per share.

Offerings

AnaptysBio Announced The Pricing Of An Underwritten Offering Of 2,750,498 Shares Of Its Common Stock At A Price Of $36.50 Per Share, Representing A Premium Of Around 10% To Anaptys' Closing Price On Aug. 13, 2024

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Overweight and raises the price target from $69 to $75.

JP Morgan Maintains Overweight on AnaptysBio, Raises Price Target to $75

Across the recent three months, 4 analysts have shared their insights on AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for AnaptysBio, revealing an average target of $53.25, a high estimate of $69.00, and a low estimate of $34.00. Surpassing the previous average price target of $42.00, the current average has increased by 26.79%.
<img src="https://www.benzinga.com/files/images/story/2024/1722952877_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of AnaptysBio's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AnaptysBio. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of AnaptysBio's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AnaptysBio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About AnaptysBio</h2>
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
<h3>Understanding the Numbers: AnaptysBio's Finances</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: AnaptysBio's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 422.49%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: AnaptysBio's net margin excels beyond industry benchmarks, reaching -612.01%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): AnaptysBio's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -64.67%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): AnaptysBio's ROA stands out, surpassing industry averages. With an impressive ROA of -10.24%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.36, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess AnaptysBio: What You Need To Know

AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.89) by 92.13 percent. The company reported quarterly sales of $11.00 million which missed the analyst consensus estimate of $24.30 million by 54.73 percent. This is a 217.92 percent increase over sales of $3.46 million the same period last year.

Earnings

Earnings Misses

AnaptysBio Q2 2024 Adj EPS $(1.71) Misses $(0.89) Estimate, Sales $11.00M Miss $24.30M Estimate

HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>), a clinical-stage biotechnology company focused on delivering immunology therapeutics.
AnaptysBio has a pipeline of checkpoint agonists, including rosnilimab, a PD-1 agonist in development for rheumatoid arthritis (RA) and ulcerative colitis (UC), and ANB032, a B and T cell lymphocyte attenuator (BTLA) agonist in development for atopic dermatitis (AD).
In Phase 1, rosnilimab showed a 90% reduction of T cell proliferation, inflammatory cytokine secretion and PD-1(high) T cells and demonstrated favorable safety.
Related: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37631577/skin-disease-focused-anaptysbio-earns-analyst-upgrade-on-positive-outlook-for-clini" rel="noreferrer noopener">Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers</a>.
HC Wainwright initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/ANAB/analyst-ratings" rel="noreferrer noopener">price target of $55</a>.
Targeting PD-1 high-expressing cells has been clinically derisked as a mechanism of action against rheumatoid arthritis through positive Phase 2 data from Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) peresolimab.
While peresolimab for rheumatoid arthritis has shown encouraging results, there may still be potential for improved agonist potency.
HC Wainwright suggests that rosnilimab might have a better efficacy profile than peresolimab.
They expect that the topline data from the Phase 2b trial of rosnilimab in rheumatoid arthritis, due in mid-2025, could surpass the efficacy results seen in peresolimab&#8217;s Phase 2a trial.
If rosnilimab shows JAK-like efficacy without safety concerns, HC Wainwright believes it could see substantial uptake even in the crowded UC market. They anticipate topline data in the first half of 2026, which could be a major catalyst.
ANB032 is a more high-risk/high-reward asset, given that historical studies with BTLA agonists were not positive, although these assets did not have membrane-proximal epitope binding and had weak agonist activity.
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has expanded the GS-0272 (BTLA agonist) Phase 1b study in rheumatoid arthritis (RA) from 48 to 87 patients, suggesting potential activity. This development boosts confidence in ANB032.
The analyst writes that expectations for topline Phase 2 data by the end of 2024 for AD are low, which could lead to significant upside potential, if positive.
Price Action: ANAB stock is up 3.26% at $34.80 at the last check on Monday.

Biotech

Health Care

Initiation

General

GILD

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

HC Wainwright &amp; Co. analyst Emily Bodnar initiates coverage on AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy rating and announces Price Target of $55.

HC Wainwright & Co. Initiates Coverage On AnaptysBio with Buy Rating, Announces Price Target of $55

JP Morgan analyst Anupam Rama upgrades AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Neutral to Overweight and raises the price target from $29 to $69.

Upgrades

JP Morgan Upgrades AnaptysBio to Overweight, Raises Price Target to $69

In the preceding three months, 7 analysts have released ratings for AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for AnaptysBio, presenting an average target of $50.0, a high estimate of $80.00, and a low estimate of $28.00. Surpassing the previous average price target of $30.00, the current average has increased by 66.67%.
<img src="https://www.benzinga.com/files/images/story/2024/1715374871_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive AnaptysBio is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$56.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Julian Harrison</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Alex Schwartz</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AnaptysBio. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AnaptysBio's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AnaptysBio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know AnaptysBio Better</h2>
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
<h3>AnaptysBio: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, AnaptysBio showcased positive performance, achieving a revenue growth rate of 32.27% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AnaptysBio's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -468.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): AnaptysBio's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -40.49%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): AnaptysBio's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -8.98%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: AnaptysBio's debt-to-equity ratio surpasses industry norms, standing at 0.2. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 7 Takes On AnaptysBio

Wedbush analyst David Nierengarten reiterates AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Outperform and maintains $34 price target.

Wedbush Reiterates Outperform on AnaptysBio, Maintains $34 Price Target

AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(1.57) by 4.46 percent. The company reported quarterly sales of $7.180 million which beat the analyst consensus estimate of $3.967 million by 80.98 percent. This is a 422.56 percent increase over sales of $1.374 million the same period last year.

Earnings Beats

AnaptysBio Q1 2024 Adj EPS $(1.64) Misses $(1.57) Estimate, Sales $7.180M Beat $3.967M Estimate

<ul>
<li>All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least 24 weeks maintained clear to almost clear skin and none experienced a flare</li>
<li>Of the remaining eight responding patients from GEMINI-1 re-randomized to placebo in GEMINI-2, 25% maintained clear to almost clear skin and 63% of these patients experienced a flare</li>
<li>Safety and tolerability in GEMINI-2 patients was consistent with reported profile from GEMINI-1</li>
<li>Plan to submit a comprehensive data abstract for GEMINI-1 and GEMINI-2 to a H2 2024 medical meeting</li>
<li>Intend to out-license imsidolimab in 2024 &nbsp;</li>
</ul>
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP), a severe orphan disease that is potentially life-threatening if left untreated.
In the 45-patient GEMINI-1 Phase 3 trial, patients were randomized 1:1:1 to receive a single infusion of 750mg intravenous (IV) imsidolimab, 300mg IV imsidolimab or placebo at Day 0. Of the patients who received a single dose of 750mg IV imsidolimab, 53% achieved a GPP Physician Global Assessment (GPPPGA) score of 0/1 (clear or almost clear skin) at Week 4 (primary endpoint), compared to 13% of the patients on placebo (p=0.0131). Of the patients who received a single dose of 300mg IV imsidolimab, 53% achieved GPPPGA 0/1 at Week 4.
Sixteen GPPPGA 0/1 responder patients from GEMINI-1 were subsequently re-randomized to monthly maintenance dosing of either 200mg subcutaneous (SC) imsidolimab or placebo in the GEMINI-2 Phase 3 trial. Patients were followed for at least 24 weeks and up to a maximum of 92 weeks. Of the eight responding patients from GEMINI-1 who were re-randomized to monthly 200mg SC imsidolimab maintenance therapy, 100% maintained a GPPPGA score of 0/1 and none of them experienced a flare. Of the remaining eight responding patients from GEMINI-1 who were re-randomized to placebo, 25% maintained a GPPPGA score of 0/1 and 63% experienced a flare.

Anaptys Top-Line GEMINI-2 Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis; Patients Who Received A Single Dose Of 750mg IV Imsidolimab, 53% Achieved A GPP Physician Global Assessment Score Of 0/1 (Clear Or Almost Clear Skin) At Week 4

<ul>
<li>Anaptys to receive $50 million upfront cash payment from Sagard Healthcare &nbsp;</li>
<li>Prior agreement amended to now expire once Sagard receives a capped payoff of either $600 million if received by March 31, 2031 or $675 million if received thereafter</li>
</ul>
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the execution of an amended agreement with Sagard Healthcare for additional Anaptys Jemperli (dostarlimab) royalties. Anaptys intends to utilize the proceeds of the transaction to continue the broad development of its immune cell modulators (ICMs), including its best-in-class checkpoint agonists, in heterogeneous, systemic autoimmune and inflammatory diseases.

Contracts

Anaptys To Receive $50M Upfront Cash Payment From Sagard Healthcare From Amended Agreement In Exchange For Additional Jemperli Royalties

Cytek Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctkb#NASDAQ">CTKB</a>) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 80%. A quarter ago, it was expected that this company would post earnings of $0.03 per share when it actually produced earnings of $0.07, delivering a surprise of 133.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Cytek Biosciences, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $44.86 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 2.28%. This compares to year-ago revenues of $37.09 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
Cytek Biosciences shares have lost about 30% since the beginning of the year versus the S&amp;P 500&#39;s gain of 8.8%.
What&#39;s Next for Cytek Biosciences?
While Cytek Biosciences has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Cytek Biosciences: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $49.01 million in revenues for the coming quarter and $0.03 on $207.96 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, AnaptysBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anab#NASDAQ">ANAB</a>), has yet to report results for the quarter ended March 2024.
This company is expected to post quarterly loss of $1.54 per share in its upcoming report, which represents a year-over-year change of +2.5%. The consensus EPS estimate for the quarter has been revised 1.3% higher over the last 30 days to the current level.
AnaptysBio, Inc.&#39;s revenues are expected to be $4.55 million, up 232.1% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2271052/cytek-biosciences-inc-ctkb-reports-q1-loss-tops-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2271052">To read this article on Zacks.com click here.</a>

CTKB

Cytek Biosciences, Inc. Reports Q1 Loss, Tops Revenue Estimates

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $55.00. Emily B...

Buy Rating on AnaptysBio: High Potential for Upcoming Drug Candidates ANB032 and Rosnilimab

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $42.00. The compa...

Wedbush Reaffirms Their Buy Rating on AnaptysBio (ANAB)

Analyst David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report) and keeping the price target at $47.00....

Buy Rating Justified by AnaptysBio's Strategic Execution and Pipeline Potential

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AnaptysBio (ANAB – Research Report), Charles River...

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Charles River Labs (CRL) and Akero Therapeutics (AKRO)

AnaptysBio prices $100M equity offering

AnaptysBio (ANAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wa...

AnaptysBio: Strong Buy Rating on Robust Equity Raise and Promising Clinical Pipeline

Truist Financial analyst Joon Lee maintained a Hold rating on AnaptysBio (ANAB – Research Report) today and set a price target of $20.00. The compa...

Truist Financial Sticks to Its Hold Rating for AnaptysBio (ANAB)

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Leerink Partners analyst David Risinger has maintained their bullish stance on ANAB stock, giving a Buy rating on August 14. David Risinger has giv...

AnaptysBio's Strong Investor Confidence and Promising Drug Pipeline Justify Buy Rating

Small-cap and mid-cap Health Care has room to rally - Roth MKM

ABBV

ACHC

ADMA

AGIO

AKRO

BDTX

BLFS

GEHC

GMED

HALO

ILMN

LGND

MLAB

PODD

PSCH

REGN

SNYNF

SUPN

Press Releases

Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference

Anaptys to Present at TD Cowen's 44th Annual Health Care Conference  and 2024 AAD Annual Meeting

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Actym Therapeutics Appoints Thomas Smart as CEO

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

AnaptysBio

AnaptysBio (ANAB) Forecast

AnaptysBio (NASDAQ:ANAB) Stock, Quote.Headers.trade-ideas